Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$27.4M
Filings
143
Firms Hired
5
Active Period
1999–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 1231
American Health Care Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 1628
Protect Medical Innovation Act of 2018
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 184
Health Care Choice Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 314
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 878
Implementation of Food and Drug Safety and Innovation Act (FDASIA) Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 204, Trickett Wendler Right to Try Act of 2017 H.R. 878, Right to Try Act of 2017
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 878
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 191
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 204
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Food and Drug Safety and Innovation Act (FDASIA) Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 204, Trickett Wendler Right to Try Act of 2017 H.R. 878, Right to Try Act of 2017
Client expense: $210,000 · Firm income: —
Matched citations: S. 204
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 456
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 1231
American Health Care Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 1628
Protect Medical Innovation Act of 2018
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 184
Health Care Choice Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 314
Implementation of Food and Drug Safety and Innovation Act (FDASIA) Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 204, Trickett Wendler Right to Try Act of 2017 H.R. 878, Right to Try Act of 2017
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 878
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 878
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 191
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Food and Drug Safety and Innovation Act (FDASIA) Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 204, Trickett Wendler Right to Try Act of 2017 H.R. 878, Right to Try Act of 2017
Client expense: $210,000 · Firm income: —
Matched citations: S. 204
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
2017 · first_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 204
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Client expense: $210,000 · Firm income: —
Matched citations: S. 456
Establishing the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
2016 · fourth_quarter · Firm: GENZYME CORPORATION
Funding for FDA and NIH Issues and policies related to FY 2017 Appropriations and all applicable amendments H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R.3762, To provide for reconciliation pursuant to section 2002 of the concurrent resolution on the budget for FY 2016 Issues and policies related to H.Con.Res. 125, House FY 2017 budget resolution and all applicable amendments
Client expense: $260,000 · Firm income: —
Matched citations: H.Con.Res. 125
Food and Drug Administration Safety Over Sequestration Act of 2015
2016 · fourth_quarter · Firm: GENZYME CORPORATION
Funding for FDA and NIH Issues and policies related to FY 2017 Appropriations and all applicable amendments H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R.3762, To provide for reconciliation pursuant to section 2002 of the concurrent resolution on the budget for FY 2016 Issues and policies related to H.Con.Res. 125, House FY 2017 budget resolution and all applicable amendments
Client expense: $260,000 · Firm income: —
Matched citations: H.R. 1078
Food and Drug Administration Safety Over Sequestration Act of 2015
2016 · fourth_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workforces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016
Client expense: $260,000 · Firm income: —
Matched citations: H.R. 1078
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
2016 · fourth_quarter · Firm: GENZYME CORPORATION
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workforces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016
Client expense: $260,000 · Firm income: —
Matched citations: H.R. 1130
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
2016 · fourth_quarter · Firm: GENZYME CORPORATION
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
Client expense: $260,000 · Firm income: —
Matched citations: H.R. 1130
Source: Senate LDA